VLA Stock Overview
A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Valneva SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.07 |
| 52 Week High | €4.30 |
| 52 Week Low | €1.73 |
| Beta | 1.02 |
| 1 Month Change | 7.69% |
| 3 Month Change | -24.16% |
| 1 Year Change | -47.86% |
| 3 Year Change | -85.44% |
| 5 Year Change | -32.07% |
| Change since IPO | -81.09% |
Recent News & Updates
Recent updates
Valneva SE's (EPA:VLA) 25% Dip In Price Shows Sentiment Is Matching Revenues
Nov 22
€6.97: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results
Nov 10Revenues Working Against Valneva SE's (EPA:VLA) Share Price Following 29% Dive
Sep 19Valneva SE (EPA:VLA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 17Valneva SE (EPA:VLA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 10Valneva SE's (EPA:VLA) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Apr 05Analyst Forecasts Just Became More Bearish On Valneva SE (EPA:VLA)
Mar 27Is Valneva (EPA:VLA) Weighed On By Its Debt Load?
Mar 15News Flash: Analysts Just Made A Captivating Upgrade To Their Valneva SE (EPA:VLA) Forecasts
Jan 06Valneva (EPA:VLA) Has Debt But No Earnings; Should You Worry?
Dec 13Does Valneva (EPA:VLA) Have A Healthy Balance Sheet?
Aug 10Valneva SE's (EPA:VLA) Business And Shares Still Trailing The Industry
May 12Valneva (EPA:VLA) Takes On Some Risk With Its Use Of Debt
Jan 30Shareholder Returns
| VLA | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -3.9% | -4.1% | 3.8% |
| 1Y | -47.9% | -27.1% | 4.3% |
Return vs Industry: VLA underperformed the French Biotechs industry which returned -27.1% over the past year.
Return vs Market: VLA underperformed the French Market which returned 4.3% over the past year.
Price Volatility
| VLA volatility | |
|---|---|
| VLA Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 7.2% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.3% |
| 10% least volatile stocks in FR Market | 2.4% |
Stable Share Price: VLA's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: VLA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 700 | Thomas Lingelbach | valneva.com |
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.
Valneva SE Fundamentals Summary
| VLA fundamental statistics | |
|---|---|
| Market cap | €336.43m |
| Earnings (TTM) | -€7.42m |
| Revenue (TTM) | €158.54m |
2.1x
P/S Ratio-45.4x
P/E RatioIs VLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VLA income statement (TTM) | |
|---|---|
| Revenue | €158.54m |
| Cost of Revenue | €163.61m |
| Gross Profit | -€5.08m |
| Other Expenses | €2.34m |
| Earnings | -€7.42m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 20, 2025
| Earnings per share (EPS) | -0.046 |
| Gross Margin | -3.20% |
| Net Profit Margin | -4.68% |
| Debt/Equity Ratio | 79.4% |
How did VLA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 03:21 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Valneva SE is covered by 25 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stéphan Dubosq | Arkeon Finance |
| Jean-Jacques Le Fur | Bryan Garnier & Co |
| Bruno Bulic | Bryan Garnier & Co |